Friday, July 10, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Oncodesign SA”

7 pharma patents match "Oncodesign SA" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 7
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 7 pharmaceutical patents matching "Oncodesign SA" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

7 results for “Oncodesign SA” · 30,257 patents in full index Clear search

  1. US 10716869

    Radiolabeled macrocyclic EGFR inhibitor

    Oncodesign SA · Granted Jul 21, 2020 · Expires Jul 16, 2040

    granted

  2. US 10676486

    Macrocyclic RIP2 kinase inhibitors

    Oncodesign SA · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted

  3. US 10377772

    Macrocyclic LRRK2 kinase inhibitors

    Oncodesign SA · Granted Aug 13, 2019 · Expires Aug 8, 2039

    granted

  4. US 9586975

    Macrocyclic salt-inducible kinase inhibitors

    Oncodesign SA · Granted Mar 7, 2017 · Expires Mar 2, 2037

    granted

  5. US 9370519

    Macrocyclic FLT3 kinase inhibitors

    Oncodesign SA · Granted Jun 21, 2016 · Expires Jun 16, 2036

    granted

  6. US 9096609

    Macrocyclic LRRK2 kinase inhibitors

    Oncodesign SA · Granted Aug 4, 2015 · Expires Jul 30, 2035

    granted

  7. US 9090630

    Macrocyclic FLT3 kinase inhibitors

    Oncodesign SA · Granted Jul 28, 2015 · Expires Jul 23, 2035

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.